Ocular Therapeutix Stock News

The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy an

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life th

Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Does Ocular Therapeutix (OCUL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

While people tend to avoid price hikes, certain stocks up 100% this year just might provide an exception to the rule. Basically, not even two months have passed by.

The average of price targets set by Wall Street analysts indicates a potential upside of 64.6% in Ocular Therapeutix (OCUL). While the effectiveness of this highly sought-after metric is questionable,

Ocular Therapeutix and Fat Brands have solid growth and momentum in SA Quant Factor Grades with potentially high upside in line with consensus price targets. Ocular Therapeutix is up over 50% in the p

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i

Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progre

The consensus price target hints at a 134.8% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin

Ocular Therapeutix (OCUL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.